Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology
- Date 29 Mar 2021
Biofidelity Ltd, the cancer diagnostics company, today announces that the first peer review article detailing its novel ASPYRE technology has been published in Scientific Reports, a Nature journal. The article, titled "Single-copy detection of somatic variants from solid and liquid biopsy" is freely available online at www.nature.com/articles/s41598-021-85545-3.
As well as detailing the novel technology behind ASPYRE, the publication evidences the flexibility of Biofidelity’s breakthrough approach, through its application to the detection of a variety of key genetic mutations used to guide treatment decisions in lung cancer.
You might also be interested in these articles
Cambridge Future Tech Expands its Board with the Appointment of Michael Beer and Jem Davies as Non-Executive Directors
Leading DeepTech Venture-Builder Further Strengthens its Unique Position to Cultivate Innovative Technologies with the Addition of Seasoned Industry Professionals
Sun 14 Apr 2024
Cambridge Future Tech
Xampla welcomes former P&G chemist to team as scale-up accelerates
accelerates CREATOR of plastic-free, natural materials, Xampla, continues to scale-up the commercialisation of its biodegradable Morro materials with new industry hire.
Fri 1 Mar 2024
Xampla Ltd
Cambridge Future Tech Marks a Milestone with Its Inaugural London Pitch Event
Thu 22 Feb 2024
Cambridge Future Tech
